TY - JOUR T1 - Pulmonary hypertension: a paradigm for rare pulmonary diseases JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0120-2017 VL - 26 IS - 146 SP - 170120 AU - Sergio Harari Y1 - 2017/12/31 UR - http://err.ersjournals.com/content/26/146/170120.abstract N2 - This year's final issue of the European Respiratory Review (ERR) features a series of articles on pulmonary hypertension, selected from some of the contributions presented in March 2017 in Vienna (Austria) at the Pulmonary Hypertension Forum organised yearly by Actelion Pharmaceuticals Ltd (Allschwil, Switzerland). A reader might wonder why our journal, like many others in the respiratory and cardiological fields, dedicates so much attention to pulmonary hypertension (an important but rare condition) compared to more common diseases. The answer lies in the great advances that research has made in this field over the last two decades. These advances have been translated into a real revolution in the approach to the disease and the patients, with important improvements in prognosis and quality of life, as already highlighted in a recent editorial [1]. Thanks to the joint efforts of the medical community and of the industry, in a healthy and transparent collaboration, pulmonary hypertension has become both an example and a paradigm of a successful approach to rare diseases, with the development of new effective drugs, the involvement of patient associations, and attention raised among the scientific community, which is often focused on less complex and more widespread diseases.Pulmonary hypertension has become a paradigm for a successful approach to rare diseases in the respiratory field http://ow.ly/7y3l30gN0hq ER -